Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2022

Open Access 01-12-2022 | Breast Cancer | Primary research

LINC00662 enhances cell progression and stemness in breast cancer by MiR-144-3p/SOX2 axis

Authors: Congjing An, Zhigang Hu, Yuehong Li, Pengxin Zhao, Runtian Liu, Qing Zhang, Peiling Zhu, Yanting Li, Ying Wang

Published in: Cancer Cell International | Issue 1/2022

Login to get access

Abstract

Background

Breast cancer (BC) is one of the most prevalent malignancies among women globally. Emerging evidence indicates that long non-coding RNAs (lncRNAs) are associated with BC carcinogenesis. In the current study, we explored the mechanism by which LINC00662 regulates BC.

Methods

Quantitative real-time PCR (qRT-PCR) assessed RNA expressions while western blot for protein levels. Kaplan Meier analysis evaluated overall survival (OS). Cytoplasmic/nuclear fractionation, RNA binding protein immunoprecipitation (RIP) and luciferase reporter assays probed into the underlying molecular mechanism of LINC00662 in BC. Xenograft model was established to explore the influence of LINC00662 on BC progression in vivo. R square graphs were utilized to represent RNA relationships.

Results

LINC00662 is overtly overexpressed in BC tissues and cell lines. LINC00662 knockdown hampers cell proliferation, migration, invasion and stemness. LINC00662 expression is negatively correlated with OS of BC patients. LINC00662 up-regulates SOX2 expression by competitively binding to miR-144-3p, thereby modulating BC cell progression. Xenograft experiments verified that LINC00662 promotes BC tumor growth and cell stemness in vivo.

Conclusion

LINC00662 enhances cell proliferation, migration, invasion and stemness in BC by targeting miR-144-3p/SOX2 axis. The findings in the present study suggested that LINC00662 could be a potential therapeutic target for BC treatment.

Graphical Abstract

Appendix
Available only for authorised users
Literature
1.
2.
Nagini S. Breast cancer: current molecular therapeutic targets and new players. Anticancer Agents Med Chem. 2017;17(2):152–63.PubMedCrossRef
3.
Kawaguchi T, Foster BA, Young J, Takabe K. Current update of patient-derived xenograft model for translational breast cancer research. J Mammary Gland Biol Neoplasia. 2017;22(2):131–9.PubMedPubMedCentralCrossRef
4.
Ishkineeva FF, Ozerova KA, Kaveeva AD, Husnullina ES. The population need in genetic tests for predisposition to breast cancer. Problemy Sotsial’noi Gigieny, Zdravookhraneniia i Istorii Meditsiny. 2018;26(5):276–81.PubMed
5.
Yao Y, Zhang T, Qi L, Zhou C, Wei J, Feng F, Liu R, Sun C. Integrated analysis of co-expression and ceRNA network identifies five lncRNAs as prognostic markers for breast cancer. J Cell Mol Med. 2019;23(12):8410–9.PubMedPubMedCentralCrossRef
6.
Xu J, Bai J, Zhang X, Lv Y, Gong Y, Liu L, Zhao H, Yu F, Ping Y, Zhang G, et al. A comprehensive overview of lncRNA annotation resources. Brief Bioinform. 2017;18(2):236–49.PubMed
7.
Ferre F, Colantoni A, Helmer-Citterich M. Revealing protein-lncRNA interaction. Brief Bioinform. 2016;17(1):106–16.PubMedCrossRef
8.
Bhan A, Soleimani M, Mandal SS. Long Noncoding RNA and Cancer: A New Paradigm. Can Res. 2017;77(15):3965–81.CrossRef
9.
Renganathan A, Felley-Bosco E. Long noncoding RNAs in cancer and therapeutic potential. Adv Exp Med Biol. 2017;1008:199–222.PubMedCrossRef
10.
Chi JR, Yu ZH, Liu BW, Zhang D, Ge J, Yu Y, Cao XC. SNHG5 promotes breast cancer proliferation by sponging the miR-154-5p/PCNA Axis. Mol Ther Nucleic Acids. 2019;17:138–49.PubMedPubMedCentralCrossRef
11.
Xiao J, Yu H, Ma Z. LINC00339 promotes growth and invasiveness of hepatocellular carcinoma by the miR-1182/SKA1 pathway. Onco Targets Ther. 2019;12:4481–8.PubMedPubMedCentralCrossRef
12.
Zhou X, Li X, Yu L, Wang R, Hua D, Shi C, Sun C, Luo W, Rao C, Jiang Z, et al. The RNA-binding protein SRSF1 is a key cell cycle regulator via stabilizing NEAT1 in glioma. Int J Biochem Cell Biol. 2019;113:75–86.PubMedCrossRef
13.
Xu D, Chen Y, Yuan C, Zhang S, Peng W. Long non-coding RNA LINC00662 promotes proliferation and migration in oral squamous cell carcinoma. Onco Targets Ther. 2019;12:647–56.PubMedPubMedCentralCrossRef
14.
Cheng L, Xing Z, Zhang P, Xu W. Long non-coding RNA LINC00662 promotes proliferation and migration of breast cancer cells via regulating the miR-497-5p/EglN2 axis. Acta Biochim Pol. 2020;67(2):229–37.PubMed
15.
Xu J, Li Y, Lu J, Pan T, Ding N, Wang Z, Shao T, Zhang J, Wang L, Li X. The mRNA related ceRNA-ceRNA landscape and significance across 20 major cancer types. Nucleic Acids Res. 2015;43(17):8169–82.PubMedPubMedCentralCrossRef
16.
Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet. 2016;17(5):272–83.PubMedCrossRef
17.
Cao J, Han X, Qi X, Jin X, Li X. TUG1 promotes osteosarcoma tumorigenesis by upregulating EZH2 expression via miR-144-3p. Int J Oncol. 2017;51(4):1115–23.PubMedPubMedCentralCrossRef
18.
Hou XW, Sun X, Yu Y, Zhao HM, Yang ZJ, Wang X, Cao XC. miR-361-5p suppresses lung cancer cell lines progression by targeting FOXM1. Neoplasma. 2017;64(4):526–34.PubMedCrossRef
19.
Cheng ZX, Song YX, Wang ZY, Wang Y, Dong Y. miR-144-3p serves as a tumor suppressor by targeting FZD7 and predicts the prognosis of human glioblastoma. Eur Rev Med Pharmacol Sci. 2017;21(18):4079–86.PubMed
20.
Liu CL, Wang WH, Sun YL, Zhuang HW, Xu M, Chen HF, Liu JX. MiR-144-3p inhibits the proliferation and metastasis of pediatric Wilms’ tumor cells by regulating Girdin. Eur Rev Med Pharmacol Sci. 2018;22(22):7671–8.PubMed
21.
Liu F, Chen N, Xiao R, Wang W, Pan Z. miR-144-3p serves as a tumor suppressor for renal cell carcinoma and inhibits its invasion and metastasis by targeting MAP3K8. Biochem Biophys Res Commun. 2016;480(1):87–93.PubMedCrossRef
22.
Li H, Wang M, Zhou H, Lu S, Zhang B. Long Noncoding RNA EBLN3P promotes the progression of liver cancer via alteration of microRNA-144-3p/DOCK4 Signal. Cancer Manag Res. 2020;12:9339–49.PubMedPubMedCentralCrossRef
23.
Parashar D, Geethadevi A, Aure MR, Mishra J, George J, Chen C, Mishra MK, Tahiri A, Zhao W, Nair B, et al. miRNA551b-3p activates an oncostatin signaling module for the progression of triple-negative breast cancer. Cell Rep. 2019;29(13):4389-4406.e4310.PubMedPubMedCentralCrossRef
24.
Zhang Y, Chen F, Xiao X, Pan W, Yuan Q, Cao J. Chrysin inhibits sphere formation in SMMC-7721 cells via modulation of SHP-1/STAT3 signaling pathway. Cancer Manag Res. 2019;11:2977–85.PubMedPubMedCentralCrossRef
25.
Song M, Sun M, Xia L, Chen W, Yang C. miR-19b-3p promotes human pancreatic cancer Capan-2 cells proliferation by targeting phosphatase and tension homolog. Ann Transl Med. 2019;7(11):236.PubMedPubMedCentralCrossRef
26.
Bhuria V, Xing J, Scholta T, Bui KC, Nguyen MLT, Malek NP, Bozko P, Plentz RR. Hypoxia induced Sonic Hedgehog signaling regulates cancer stemness, epithelial-to-mesenchymal transition and invasion in cholangiocarcinoma. Exp Cell Res. 2019;385(2):111671.PubMedCrossRef
27.
Zhang J, Xiao C, Feng Z, Gong Y, Sun B, Li Z, Lu Y, Fei X, Wu W, Sun X, et al. SOX4 promotes the growth and metastasis of breast cancer. Cancer Cell Int. 2020;20:468.PubMedPubMedCentralCrossRef
28.
Piva M, Domenici G, Iriondo O, Rábano M, Simões BM, Comaills V, Barredo I, López-Ruiz JA, Zabalza I, Kypta R, et al. Sox2 promotes tamoxifen resistance in breast cancer cells. EMBO Mol Med. 2014;6(1):66–79.PubMedCrossRef
29.
30.
Jarroux J, Morillon A, Pinskaya M. History, discovery, and classification of lncRNAs. Adv Exp Med Biol. 2017;1008:1–46.PubMedCrossRef
31.
Song C, Sun P, He Q, Liu LL, Cui J, Sun LM. Long non-coding RNA LINC01287 promotes breast cancer cells proliferation and metastasis by activating Wnt/ss-catenin signaling. Eur Rev Med Pharmacol Sci. 2019;23(10):4234–42.PubMed
32.
Cao Z, Wu P, Su M, Ling H, Khoshaba R, Huang C, Gao H, Zhao Y, Chen J, Liao Q, et al. Long non-coding RNA UASR1 promotes proliferation and migration of breast cancer cells through the AKT/mTOR pathway. J Cancer. 2019;10(9):2025–34.PubMedPubMedCentralCrossRef
33.
Gong W, Su Y, Liu Y, Sun P, Wang X. Long non-coding RNA Linc00662 promotes cell invasion and contributes to cancer stem cell-like phenotypes in lung cancer cells. J Biochem. 2018;164(6):461–9.PubMedCrossRef
34.
Liu Z, Yao Y, Huang S, Li L, Jiang B, Guo H, Lei W, Xiong J, Deng J. LINC00662 promotes gastric cancer cell growth by modulating the Hippo-YAP1 pathway. Biochem Biophys Res Commun. 2018;505(3):843–9.PubMedCrossRef
35.
Luo J, Yao Y, Ji S, Sun Q, Xu Y, Liu K, Diao Q, Qiang Y, Shen Y. PITX2 enhances progression of lung adenocarcinoma by transcriptionally regulating WNT3A and activating Wnt/β-catenin signaling pathway. Cancer Cell Int. 2019;19:96.PubMedPubMedCentralCrossRef
36.
Zhang L, Chen S, Wang B, Su Y, Li S, Liu G, Zhang X. An eight-long noncoding RNA expression signature for colorectal cancer patients’ prognosis. J Cell Biochem. 2019;120(4):5636–43.PubMedCrossRef
37.
Tian X, Wu Y, Yang Y, Wang J, Niu M, Gao S, Qin T, Bao D. Long noncoding RNA LINC00662 promotes M2 macrophage polarization and hepatocellular carcinoma progression via activating Wnt/β-catenin signaling. Mol Oncol. 2020;14(2):462–83.PubMedCrossRef
38.
Li N, Zhang LY, Qiao YH, Song RJ. Long noncoding RNA LINC00662 functions as miRNA sponge to promote the prostate cancer tumorigenesis through targeting miR-34a. Eur Rev Med Pharmacol Sci. 2019;23(9):3688–98.PubMed
39.
Yao Z, Xu D, Li Z, Yao J, Pan Z, Chen J. Long intergenic non-coding RNA LINC00662 contributes to malignant growth of colorectal cancer cells by upregulating c-myc via sponging microRNA-145. Biosci Rep. 2020;90:345.
40.
Cheng B, Rong A, Zhou Q, Li W. LncRNA LINC00662 promotes colon cancer tumor growth and metastasis by competitively binding with miR-340-5p to regulate CLDN8/IL22 co-expression and activating ERK signaling pathway. J Exp Clin Cancer Res. 2020;39(1):5.PubMedPubMedCentralCrossRef
41.
Wang H, Yu M, Hu W, Chen X, Luo Y, Lin X, Zeng Y, Yao X. Linc00662 promotes tumorigenesis and progression by regulating miR-497-5p/AVL9 Axis in Colorectal Cancer. Front Genet. 2019;10:1385.PubMedCrossRef
42.
Wu G, Zhou H, Li D, Zhi Y, Liu Y, Li J, Wang F. LncRNA DANCR upregulation induced by TUFT1 promotes malignant progression in triple negative breast cancer via miR-874–3p-SOX2 axis. Exp Cell Res. 2020;396(2):112331.PubMedCrossRef
43.
Shen H, Wang Y, Shi W, Sun G, Hong L, Zhang Y. LncRNA SNHG5/miR-26a/SOX2 signal axis enhances proliferation of chondrocyte in osteoarthritis. Acta Biochim Biophys Sin. 2018;50(2):191–8.PubMedCrossRef
Metadata
Title
LINC00662 enhances cell progression and stemness in breast cancer by MiR-144-3p/SOX2 axis
Authors
Congjing An
Zhigang Hu
Yuehong Li
Pengxin Zhao
Runtian Liu
Qing Zhang
Peiling Zhu
Yanting Li
Ying Wang
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2022
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-022-02576-0

Other articles of this Issue 1/2022

Cancer Cell International 1/2022 Go to the issue

Review

Current methods for studying metastatic potential of tumor cells

Primary research

PGM1 suppresses colorectal cancer cell migration and invasion by regulating the PI3K/AKT pathway

Review

Myeloid cell leukemia-1 expression in cancers of the oral cavity: a scoping review

Research

Lymphocyte antigen 6G6D-mediated modulation through p38α MAPK and DNA methylation in colorectal cancer

Research

Comprehensive analysis of the prognostic implications and functional exploration of PAK gene family in human cancer

Review

A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits